Nicotinamide - Biorunx

Drug Profile

Nicotinamide - Biorunx

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chungbuk National University
  • Developer Biorunx; Chungbuk National University
  • Class Amides; Antiacnes; Antibacterials; Nicotinic-acids; Small molecules; Vitamins
  • Mechanism of Action Cytokine modulators; DNA-binding protein stimulants; Leukocyte modulators; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in South Korea (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top